Radioligand therapy has been around for a long time, but 2025 was the year it started to look less like a niche tool and more like something oncology teams have to actively plan for. In March 2025, ...

Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.

Delve into the Astellas playbook, a strategy relying on "strategic brand" and advancing on "primary focuses" at the same time ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Delve into the Amarin v. Hikma case in which the U.S. Supreme Court might settle the skinny label question once and for all.

Discover how AI is transforming biologics discovery, tackling adoption challenges, and driving growth in the biologics market.

The healthcare funding landscape was not particularly kind to the U.K. in 2025. Following Merck pulling out of its $1 billion expansion plans in London, it was evident that life science investments in ...

Italy’s biotech ecosystem might be slightly smaller and less visible than some other European hubs, but it is home to a growing number of companies advancing ambitious therapeutic programs. From gene ...

Biotech enters 2026 with scientific momentum, new modalities continue to mature, data readouts are accumulating across oncology, metabolic disease, and neurology, and the industry’s toolkit is broader ...

CRISPR technology offers the promise to cure human genetic diseases with gene editing. This promise became a reality when the world’s first CRISPR therapy was approved by regulators to treat patients ...